• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

Teva Announces Philadelphia-Area Layoffs

americanpharmaceuticacreviewJanuary 23, 2018

Tag: Teva Announces , layoffs , Generic

Teva Pharmaceuticals will lay off 208 people this year at their Pennsylvania-based locations, according to notices filed with the Pennsylvania Department of Labor and Industry.

The Israeli generic drug maker, which has its U.S. headquarters located in North Wales, Pa., announced at the end of 2017 it would eliminate 14,000 positions globally over the next two years.

The company notified state regulators that it will cut 65 jobs at two locations in North Wales and Horsham, 47 jobs in West Chester, and 96 jobs in Frazer and Great Valley. The notices were listed as layoffs, scheduled to take place by the end of 2018.

Previous:New Player Joining, what will be Its Odds of Success in Marching into the Hypoglycemic Drug Market?

Next:Group Health Cooperative Eau Claire Partners with Valera in Innovative Behavioral Health Management

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Teva Announces Philadelphia-Area Layoffs | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Nasal pump for Generics

Nasal pump for Generics
20mm crimp on nasal pump, Dosed, Generic to, AB rated

20mm crimp on nasal pump, Dosed, Generic to, AB rated
Generic Diskus

Generic Diskus
Generic Breezhaler

Generic Breezhaler
Generic Soft Mist Inhaler

Generic Soft Mist Inhaler
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service